Small Benchtop Analyzer Offers Large Menu of Chemical Tests
|
By LabMedica International staff writers Posted on 24 Sep 2008 |
|
A new benchtop chemistry analyzer provides a menu of over 100 tests. With low operating costs, it is suitable as a backup analyzer for hospitals or as a primary analyzer for small hospitals and physician office laboratories where space is a limited.
Called the BioLis 24i, the analyzer can perform 400-test per hour and has a menu of over 100 chemistries. Requiring only 31 inches (approximately 75 cm) of bench space, the instrument's large menu includes comprehensive metabolic, basic, hepatic, renal, anemia, and lipid panel tests. It also tests for specific proteins including immunoglobulins, C3, C4, transferrin, haptoglobin, antistreptolysin (ASO), rheumatoid factor (RF), C-reactive protein (CRP), prealbumin, and Apo lipoprotein (APO) lipoproteins. In addition, the analyzer can perform diabetic screening tests and tests for therapeutic drugs and drugs of abuse.
The analyzer has permanent cuvettes and a distilled water system. A thorough 10-step cuvette wash station administers heated alkaline and acid washes before and after each run prevents carryover. Positive sample ID and elimination of instrument programming are achieved with bidirectional interface and barcoded primary tube sampling. A laboratory information system (LIS) interface into electronic medical records (EMR) is also easily achieved. Thirty-day onboard reagent stability and 14-day calibration stability make daily start up a matter of running quality control (QC).
BioLis 24i is a marketed by Carolina Chemistries (Los Angeles, CA, USA). The company's technical representatives and service engineers install the analyzer and provide training in its use. The BioLis 24i is installed with a water system and drain into a sink. Electrical requirement of 110 VAC allow it to be installed anywhere.
Related Links:
Carolina Chemistries
Called the BioLis 24i, the analyzer can perform 400-test per hour and has a menu of over 100 chemistries. Requiring only 31 inches (approximately 75 cm) of bench space, the instrument's large menu includes comprehensive metabolic, basic, hepatic, renal, anemia, and lipid panel tests. It also tests for specific proteins including immunoglobulins, C3, C4, transferrin, haptoglobin, antistreptolysin (ASO), rheumatoid factor (RF), C-reactive protein (CRP), prealbumin, and Apo lipoprotein (APO) lipoproteins. In addition, the analyzer can perform diabetic screening tests and tests for therapeutic drugs and drugs of abuse.
The analyzer has permanent cuvettes and a distilled water system. A thorough 10-step cuvette wash station administers heated alkaline and acid washes before and after each run prevents carryover. Positive sample ID and elimination of instrument programming are achieved with bidirectional interface and barcoded primary tube sampling. A laboratory information system (LIS) interface into electronic medical records (EMR) is also easily achieved. Thirty-day onboard reagent stability and 14-day calibration stability make daily start up a matter of running quality control (QC).
BioLis 24i is a marketed by Carolina Chemistries (Los Angeles, CA, USA). The company's technical representatives and service engineers install the analyzer and provide training in its use. The BioLis 24i is installed with a water system and drain into a sink. Electrical requirement of 110 VAC allow it to be installed anywhere.
Related Links:
Carolina Chemistries
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Automatic CLIA Analyzer
Shine i9000
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read more
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channel
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Microbiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more
AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
Pathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read more
Industry
view channel
New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more